SCHEMBL6271714

SCHEMBL6271714

CCc1ccc(CC[O])cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.52
▸ TP53 P04637 1/20 0.46
▸ CA2 P00918 1/20 0.44
▸ CYP2A6 P11509 1/20 0.42
▸ LPL P06858 1/20 0.42
▸ LIPG Q9Y5X9 1/20 0.42
▸ MGLL Q99685 2/20 0.41
▸ PLK1 P53350 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ GPR84 Q9NQS5 2/20 0.40
▸ EGFR P00533 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ PLAU P00749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10540891 0.85 GFER (0.42) TAAR1ALDH1A1CA2CYP2A6L3MBTL1
SCHEMBL18242000 0.84 TAAR1 (0.52) TAAR1ALDH1A1TP53CA2CYP2A6
SCHEMBL10344423 0.83 CA2 (0.52) ALDH1A1CA2LPLLIPGMGLL
SCHEMBL18242675 0.82 TAAR1 (0.50) TAAR1ALDH1A1TP53CA2LPL
SCHEMBL6546733 0.82 TAAR1 (0.68) TAAR1ALDH1A1TP53CA2CYP2A6
SCHEMBL9027693 0.80 TAAR1 (0.48) TAAR1ALDH1A1TP53LPLLIPG
SCHEMBL9891050 0.80 TAAR1 (0.59) TAAR1ALDH1A1TP53CA2CYP2A6
SCHEMBL10841583 0.79 ALDH1A1 (0.57) ALDH1A1TP53CA2PLK1L3MBTL1
SCHEMBL36295 0.78 TP53 (0.67) TAAR1ALDH1A1TP53CA2CYP2A6
SCHEMBL1805218 0.78 CYP1A2 (0.56) TAAR1ALDH1A1TP53CYP2A6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114920744-B Non-covalent BTK kinase inhibitor and biological application thereof 中国药科大学 2024-05-07 — — CN disclosed
CN-116375715-A Compound serving as non-covalent BTK kinase inhibitor and biological application thereof 中国药科大学 2023-07-04 — — CN disclosed
CN-114920744-A Non-covalent BTK kinase inhibitor and biological application thereof 中国药科大学 2022-08-19 — — CN disclosed
US-10451967-B2 Acid- and radical-generating agent and method for generating acid and radical FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2019-10-22 — — US disclosed
US-20160342084-A1 ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2016-11-24 — — US disclosed
EP-1000620-B1 Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBITORS TAIHO PHARMACEUTICAL CO LTD (JP) 2005-12-07 — — EP disclosed
EP-0454501-B1 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides SANKYO CO (JP) 2001-09-05 — — EP disclosed
US-6166036-A Lp(a)-lowering agent and apolipoprotein (a) formation suppressing agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 — — US disclosed
EP-1000620-A1 Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-05-17 — — EP disclosed
EP-0839812-A1 Preparation of benzylthiazolidine derivatives Sankyo Company Limited (JP) 1998-05-06 — — EP disclosed
US-5387596-A Treating arteriosclerosis SANKYO COMPANY, LIMITED (JP) 1995-02-07 — — US disclosed
US-5145865-A Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1992-09-08 — — US disclosed
EP-0454501-A2 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides Sankyo Company Limited (JP) 1991-10-30 — — EP disclosed
EP-0393607-A2 Phenylcarboxylic acid derivatives having a hetero ring OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-10-24 — — EP disclosed
EP-0368670-A1 Trisubstituted piperazine compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1990-05-16 — — EP disclosed
EP-0192111-B1 ISO-UREAS, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES BASF Aktiengesellschaft (DE) 1990-05-16 — — EP disclosed
EP-0191394-B1 ISOTHIOUREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE TO COMBAT UNDESIRABLE PLANT GROWTH BASF Aktiengesellschaft (DE) 1989-12-06 — — EP disclosed
US-4692187-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1987-09-08 — — US disclosed
US-4689068-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1987-08-25 — — US disclosed
EP-0192111-A1 Iso-ureas, processes for their production and their use as herbicides BASF Aktiengesellschaft (DE) 1986-08-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10451967-B2 Acid- and radical-generating agent and method for generating acid and radical CBR1, HAO2, CBR3 TAAR1 1102/4885ALDH1A1 151/4885TP53 4315/4885
US-20160342084-A1 ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL CBR1, HAO2, CBR3 TAAR1 1102/4885ALDH1A1 151/4885TP53 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback